Molecular differences in the KRAS gene mutation between a primary tumor and related metastatic sites - case report and a literature review

Folia Histochemica et Cytobiologica

Volumn 48, Issue 4, 2010, Pages 597-602

  Kosakowska, Ewa Anna ^a   Stec, Rafał ^b   Charkiewicz, Radosław ^c   Skoczek, Marta ^d   Chyczewski, Lech ^c  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d Cancer Center   (Poland)

Author keywords

Advanced colorectal cancer; KRAS gene; Targeted therapy

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; CANCER INFILTRATION; CANCER LOCALIZATION; CANCER SIZE; CASE REPORT; CHILL; COLON ADENOCARCINOMA; COLON BIOPSY; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG FEVER; EPIGASTRIC PAIN; FEMALE; GENE MUTATION; HAND FOOT SYNDROME; HEMICOLECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LIVER RESECTION; METASTASIS POTENTIAL; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; PRIMARY TUMOR; REVIEW;

EID: 79958061900     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.2478/v10042-010-0078-z     Document Type: Review

References (45)

1. Wojciechowska U, Didkowska J, Tarkowski W. Nowotwory złośliwe w Polsce 2004 roku. Warsaw: Centrum Onkologii - Instytut; 2006.
2. Cunningam D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after flurouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1407-1412.
3. Hurvitz H, Fehrenbacher L, Novoty W et al. Addition of bevacizumab (rhu MAb VEGF) to bolus IFL in the first-line treatment of patients with metastatic colorectal cancer: results of a randomized phase III trial. New Engl J Med.2004;350:2335-2342.
4. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: randomized trial. J Clin Oncol. 1992;10:904-911.
5. Ciardiello F, De Vita F, Orditura M et al. Cetuximab in the treatment of colorectal cancer colorectal cancer. Future Oncol. 2005;1:173-81.
6. Van Cutsem E, Peeters M, Siena S. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapyrefractory metastatic colorectal cancer. J Clin Oncol.2007;25:1658-64.
7. Saltz LB, Clarke S, Diaz-Dubio E et al. Bevacizumab in combination with oxaliplatin-base chemotherapy in metastatic colorectal cancer randomized phase III study. J Clin Oncol.2008;26:2013-2019.
8. Biasco G, Derenzini E, Grazi GL et al. Treatment of hepatic metastases from colorectal cancer: Many doubts, some certainties. Cancer Treat Rev. 2006;32:214-228.
9. Maindrault-Goebel et al. Oxaliplatin addend to simplified bimonthly leucovorin and 5-fluorouracil regiment as secondline therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer. 1999;35:1338-1342.
10. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol.2004;22:229-237.
11. Figueras J, Valls C, Rafecas A et al. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg. 2001;88:980-985.
12. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer. 2001;37:Suppl 4:S16-S22.
13. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. New Engl J Med.2007;357:2040-8.
14. Bokemeyer C, Bondarenko I, Hartmann JT et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol.2008;26:178s, (suppl, abstr 4000).
15. Hurwitz HI. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of KRAS mutation status: analysis of phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist. 2009;1:22-28.
16. Dobrzycka B, Terlikowski S, Kowalczuk O et al. Mutations in the KRAS gene in ovarian tumors. Folia Histochem Cytobiol.2009;47(2):221-224.
17. Wu CM, Tang R, Wang JY, Changchien CR et al. Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan. Cancer Genet Cytogenet.2005;158(1):55-60.
18. Kraus MC, Seelig MH, Linnemann U et al. The balanced induction of K-ras codon 12 and 13 mutations in mucosa differs from their ratio in neoplastic tissues. Int J Oncol.2006;29(4):957-64.
19. Brink M, de Goeij AF, Weijenberg MP et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis. 2003;24:703-710.
20. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer. 2001;85:692-696.
21. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998;74:49-139.
22. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to antiepidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643-2648.
23. Scartozzi M, Bearzi I, Berardi R et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol. 2004;22:4772-4778.
24. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-34.
25. Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer.2007;96:1166-9.
26. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced col-orectal cancer treated with cetuximab. J Clin Oncol.2008;26:374-379.
27. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer. 2001;37:Suppl 4:S16-S22.
28. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230-3237.
29. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. New Engl J Med.2004;351:337-345.
30. European Medicines Agency: Questions and answers on the marketing authorization for Vectibix. Available at: http://www.emea.europa.eu/pdfs/human/opinion/40511307en.pdf, Accessed September 20, 2007.
31. European Medicines Agency: Committee for Medicinal Products for Human Use post-authorisation summary of positive opinion for Erbitux. Available at: http://www.emea.europa.eu//pdfs/human/opinion/Erbitux_28040208en.pdf, Accessed May 30, 2008.
32. Van Cutsem E, Lang I, D'haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol.2008;26:5s, (suppl, abstr 2).
33. Oudejans JJ, Slebos RJ, Zoetmulder FA et al. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer.1991;49:875-879.
34. Suchy B, Zietz C, Rabes HM. K-ras point mutations in human colorectal carcinomas: Relation to aneuploidy and metastasis. Int J Cancer. 1992;52:30-33.
35. Al-Mulla F, Going JJ, Sowden ET et al. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol. 1998;185:130-138.
36. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl J Med. 2008; 359(17):1757-65.
37. de Reyniès A, Boige V, Milano G et al. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J Clin Oncol. 2008;26:2228-2230.
38. Scartozzi M, Bearzi I, Berardi R et al. Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: Optimising EGFR-targeted treatment options. Br J Cancer. 2007; 97:92-97.
39. Scartozzi M, Bearzi I, Berardi R et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol. 2004; 22:4772-4778.
40. Cappuzzo F, Finocchiaro G, Rossi E et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol.2008;19:717-723.
41. Artale S, Sartore-Bianchi A, Veronese SM et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 2008:1;26(25):4217-9.
42. Santini D, Loupakis F, Vincenzi B et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist.2008;13(12):1270-5. Epub 2008 Dec 4.
43. Molinari F, Martin V, Bordoni A et al. Analysis of epidermal growth factor receptor (EGFR) gene status and protein expression, and K-ras gene mutations in metastatic colorectal cancer patients: Comparison between primary tumor and related metastatic sites. Ann Oncol. 2008;19(suppl. 1):i10- i25.
44. Vehlo S, Oliviera C, Seruca R. KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases. J Clin Oncol. 2009;1:158-9.
45. Oliveira C, Velho S, Moutinho C et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene. 2007;26:158-163.